Photo-Uncaging of a Microtubule-Targeted Rigidin Analogue in Hypoxic Cancer Cells and in a Xenograft Mouse Model

• Published in: Journal of the American Chemical Society 2019-11, Vol.141 (46), p.18444-18454
• Main Authors: van Rixel, Vincent H. S, Ramu, Vadde, Auyeung, Austin B, Beztsinna, Nataliia, Leger, David Y, Lameijer, Lucien N, Hilt, Stan T, Le Dévédec, Sylvia E, Yildiz, Tugba, Betancourt, Tania, Gildner, M. Brenton, Hudnall, Todd W, Sol, Vincent, Liagre, Bertrand, Kornienko, Alexander, Bonnet, Sylvestre
• Format: Article
• Language: English
• Subjects: Cancer; Chemical Sciences; Life Sciences; Organic chemistry
• ISSN: 0002-7863; 1520-5126
• DOI: 10.1021/jacs.9b07225

Marine alkaloid rigidins are cytotoxic compounds known to kill cancer cells at nanomolar concentrations by targeting the microtubule network. Here, a rigidin analogue containing a thioether group was “caged” by coordination of its thioether group to a photosensitive ruthenium complex. In the dark, the coordinated ruthenium fragment prevented the rigidin analogue from inhibiting tubulin polymerization and reduced its toxicity in 2D cancer cell line monolayers, 3D lung cancer tumor spheroids (A549), and a lung cancer tumor xenograft (A549) in nude mice. Photochemical activation of the prodrug upon green light irradiation led to the photosubstitution of the thioether ligand by water, thereby releasing the free rigidin analogue capable of inhibiting the polymerization of tubulin. In cancer cells, such photorelease was accompanied by a drastic reduction of cell growth, not only when the cells were grown in normoxia (21% O2) but also remarkably in hypoxic conditions (1% O2). In vivo, low toxicity was observed at a dose of 1 mg·kg–1 when the compound was injected intraperitoneally, and light activation of the compound in the tumor led to 30% tumor volume reduction, which represents the first demonstration of the safety and efficacy of ruthenium-based photoactivated chemotherapy compounds in a tumor xenograft.